|Past two years||Past Year||Past 30 Days|
|Full Text Views||1||0||0|
In recent investigations Eyles and Coleman (1952) demonstrated that 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine (Daraprim) prevented death of white mice experimentally infected with a strain of Toxoplasma gondii isolated from the Norway rat. Additional studies by Eyles (1953) showed that the antitoxoplasmal action of Daraprim was enhanced by sulfadiazine.
In experimental toxoplasmosis it is well known that chemotherapy with such agents as sulfonamides, sulfones and certain antibiotics may prevent death of mice during the period of drug administration. It has been repeatedly observed however that Toxoplasma may not be eradicated from the tissues of mice and that relapse and death may occur within a variable time following cessation of therapy. It has been observed here that treated mice may survive for several months or possibly for the duration of their normal life span yet retaining foci of virulent Toxoplasma in their tissues. It is questionable therefore whether survival of Toxoplasma-infected mice during the period of experimental chemotherapy constitutes a valid criterion of drug efficacy.
This investigation was supported by a research grant (E-76C-3) from the Division of Research Grants of the National Institutes of Health, Public Health Service.